Abstract: A composition according to the present invention, when used alone, is capable of inhibiting the growth of anticancer drug-resistant cancer by overcoming anticancer drug resistance or enhancing anticancer drug sensitivity, and when co-administered with an anticancer drug, may be used very effectively for the prevention, alleviation or treatment of various cancers, especially anticancer drug-resistant cancer.

Abstract: A composition according to the present invention is capable of inhibiting the growth of cancer cells and cancer stem cells, and also is capable of very effectively inhibiting the metastasis of cancer cells to other tissues. Thus, the composition may be very effectively used not only for the prevention, amelioration or treatment of cancer, but also for the inhibition of cancer metastasis.

Abstract: Provided is a marker composition for predicting the prognosis of cancer and a method for predicting the prognosis of cancer using same and, more particularly, to a marker composition for predicting the prognosis of cancer comprising an agent for measuring an expression level of mRNA or protein thereof of at least one gene selected from the group consisting of ESR1, BEST1, ACTA2, HIPK2, IGSF9, ASCC2, JUN, PPP2R5A, SMAD3, CREBBP, EP300, and DDX5, to a method for predicting the prognosis of cancer using same, and to a method for providing information for determining a strategy for treating cancer.

Abstract: The present invention relates to a system for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage II and III gastric cancer, and an algorithm that can predict prognosis and chemotherapy responsiveness using quantitative analysis results of mRNA expression levels of a prognosis or chemotherapy responsiveness-related marker gene group and a reference gene group in advanced gastric cancer is developed, and can be used as supplementary information to determine a method for treating a gastric cancer patient.

Abstract: The present invention relates to a novel compound and a pharmaceutical composition for enhancing anticancer activity, which includes the same, and more particularly, to a pharmaceutical composition, which includes a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, thereby enhancing anticancer activity of an anticancer agent or radiation, and inducing proliferation inhibition and death of cancer cells, resulting in effectively treating cancer:

Abstract: The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.

Abstract: In the present disclosure, the effect of the TGF?/Smad3/EPB41L5 molecular mechanism on cancer cells has been identified, and it has been found that high expression of EPB41L5 is correlated with poor overall survival of cancer patients, indicating that EPB41L5 is a potential prognostic marker of cancer. Thus, the present disclosure specifies an epitope of EPB41L5 to allow EPB41L5 to be recognized as an antigen, and relates to an antibody or a fragment thereof which binds specifically to the epitope. The antibody according to the present disclosure may be usefully employed as a therapeutic agent for EPB41L5-related cancer.

Abstract: The present invention relates to a pharmaceutical composition for treating cancer, containing a polyphenol compound as an active ingredient. The pharmaceutical composition according to the present study is very effective for the treatment and prognosis-improvement of cancer stem cells or cancer tissues having a magnitude of cancer stem cells such as poorly differentiated cancer. Further, the polyphenol compound and a biguanide compound, and an anticancer agent were observed to remarkably increase inhibitory effects on the growth of cancerous cells when they were administered to cancerous cells in combination rather than individually, thus the composition is expected to find great applications in the cancer therapy field.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, which contains a glucose uptake inhibitor and a sesquiterpene lactone. The pharmaceutical composition according to the present invention is capable of effectively inhibiting the proliferation of not only cancer cells but also cancer stem cells, thereby preventing and/or treating cancer, and furthermore, preventing the resistance, metastasis and recurrence of cancer.

Abstract: The present invention relates to a pharmaceutical composition for treating cancer, containing a polyphenol compound as an active ingredient. The pharmaceutical composition according to the present study is very effective for the treatment and prognosis-improvement of cancer stem cells or cancer tissues having a magnitude of cancer stem cells such as poorly differentiated cancer. Further, the polyphenol compound and a biguanide compound, and an anticancer agent were observed to remarkably increase inhibitory effects on the growth of cancerous cells when they were administered to cancerous cells in combination rather than individually, thus the composition is expected to find great applications in the cancer therapy field.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, which contains a glucose uptake inhibitor and a sesquiterpene lactone. The pharmaceutical composition according to the present invention is capable of effectively inhibiting the proliferation of not only cancer cells but also cancer stem cells, thereby preventing and/or treating cancer, and furthermore, preventing the resistance, metastasis and recurrence of cancer.

Abstract: The present invention relates to a composition for effectively treating cancer stem cells, and more specifically to a composition for treating cancer stem cells, which contains a glucose uptake inhibitor, a biguanide-based compound, and a calcium pump inhibitor. The composition of the present invention can be used as an agent of treating cancer stem cells by effectively inducing apoptosis of the cancer stem cells. Accordingly, the composition of the present invention can be used as a pharmaceutical composition capable of effectively treating various cancer stem cells to effectively inhibiting cancer recurrence and/or metastasis.

Abstract: The present invention relates to a system for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage II and III gastric cancer, and an algorithm that can predict prognosis and chemotherapy responsiveness using quantitative analysis results of mRNA expression levels of a prognosis or chemotherapy responsiveness-related marker gene group and a reference gene group in advanced gastric cancer is developed, and can be used as supplementary information to determine a method for treating a gastric cancer patient.

Abstract: The present invention relates to an antibody that recognizes a specific motif of WLS protein so as to inhibit overactivation of the Wnt signaling pathway to thereby prevent or treat a disease associated with the Wnt signaling pathway, and to a pharmaceutical composition containing the same.

Abstract: The present invention relates to a composition for effectively treating cancer stem cells, and more specifically to a composition for treating cancer stem cells, which contains a glucose uptake inhibitor, a biguanide-based compound, and a calcium pump inhibitor. The composition of the present invention can be used as an agent of treating cancer stem cells by effectively inducing apoptosis of the cancer stem cells. Accordingly, the composition of the present invention can be used as a pharmaceutical composition capable of effectively treating various cancer stem cells to effectively inhibiting cancer recurrence and/or metastasis.

Abstract: The present invention provides novel uses of a biguanide derivative for preventing or treating glioblastoma. The compound of Formula 1 and its pharmaceutically acceptable salts can be used for preventing and treating glioblastoma. Further, the combined treatment of the compound of Formula 1 and temozolomide can provide superior effects compared to the administration of the compound of Formula 1 alone or temozolomide alone.

Abstract: The present invention provides novel uses of a biguanide derivative for preventing or treating glioblastoma. The compound of Formula 1 and its pharmaceutically acceptable salts can be used for preventing and treating glioblastoma. Further, the combined treatment of the compound of Formula 1 and temozolomide can provide superior effects compared to the administration of the compound of Formula alone or temozolomide alone.

Abstract: The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

Abstract: The present invention relates to a novel model for predicting a prognosis capable of predicting the prognosis of gastric cancer, and more specifically, to manufacturing a prediction model for predicting a clinical result after a resection during gastric cancer surgery through genetic mutation comparative analysis.

Abstract: Provided is a curable composition. The curable composition, which may provide an encapsulating material, of which processibility and workability before curing are effectively maintained and which has excellent light transmissivity, light extraction efficiency, hardness, crack resistance, adhesion strength and thermal shock resistance after curing, is provided. Further, the curable composition may show effectively controlled tackiness in the surface and may not show whitening under the high temperature or high humidity condition before or after curing.